Nom du produit:4-Guanidino-2-methoxybenzoic Acid Hydrochloride
IUPAC Name:4-carbamimidamido-2-methoxybenzoic acid hydrochloride
- CAS：1028486-08-9
- Formule moléculaire：C9H12ClN3O3
- Pureté：95%+
- Numéro de catalogue：CM324847
- Poids moléculaire：245.66
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:1028486-08-9
- Formule moléculaire:C9H12ClN3O3
- Point de fusion:-
- Code SMILES:O=C(O)C1=CC=C(NC(N)=N)C=C1OC.[H]Cl
- Densité:
- Numéro de catalogue:CM324847
- Poids moléculaire:245.66
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Alisertib
- Puma Biotechnology announced the initiation of its ALISertib in CAncer (ALISCA-Lung1) Phase II trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer. The ALISCA-Lung1 trial will enroll up to 60 patients with extensive stage small cell lung cancer who have progressed on or after first-line platinum-based chemotherapy and immunotherapy. The primary endpoint of the trial is objective response rate, with secondary endpoints of duration of response, disease control rate, progression-free survival and overall survival. Based upon the outcomes of the study, Puma anticipates meeting with the FDA to explore the potential for an accelerated approval pathway for alisertib in small cell lung cancer. Alisertib is an orally active and selective Aurora A kinase inhibitor, which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Recherche 
+86 21 5895 0110 
